In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview […]
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its
T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of
T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category
We’re proud to share that Dr. Cédric Grauffel, Manager of T-E Drug Design at T-E Meds, will be presenting at
“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate company of T-E PHARMA, will
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning
